BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, March 29, 2024
See today's BioWorld
Home
» Innovent, Lilly strike potential $1B triple PD-1 deal, largest yet for Chinese biotech
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Innovent, Lilly strike potential $1B triple PD-1 deal, largest yet for Chinese biotech
Oct. 12, 2015
By
Shannon Ellis
No Comments
SHANGHAI – Eli Lilly and Co. has deepened its relationship with Chinese biotech, Innovent Biologics Inc. in an immuno-oncology deal worth potentially $1 billion in milestone and royalty payments if all goes according to plan over the next decade.
BioWorld